NYSE · EVMN
Healthcare · Biotechnology
$9.99
Down-$0.44 (-4.22%)
Updated Sep 16, 2026, 3:00 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
EVMN closed at $9.99 after 20 trading sessions, down 29.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $10.43 | $10.43 | $9.80 | $9.99 | 520K |
| Sep 14, 2026 | $10.49 | $10.6259 | $10.31 | $10.43 | 350.2K |
| Sep 11, 2026 | $10.66 | $10.82 | $10.50 | $10.54 | 388.92K |
| Sep 10, 2026 | $10.50 | $11.03 | $10.31 | $10.56 | 692.62K |
| Sep 9, 2026 | $11.90 | $12.10 | $10.3001 | $10.84 | 3.99M |
| Sep 8, 2026 | $12.11 | $13.35 | $12.01 | $13.08 | 1.24M |
| Sep 4, 2026 | $11.87 | $12.455 | $11.87 | $12.27 | 249.09K |
| Sep 3, 2026 | $12.70 | $12.70 | $11.70 | $12.00 | 594.24K |
| Sep 2, 2026 | $12.50 | $12.80 | $12.33 | $12.48 | 370.58K |
| Sep 1, 2026 | $12.50 | $12.735 | $12.42 | $12.48 | 278.49K |
| Aug 31, 2026 | $13.08 | $13.13 | $12.61 | $12.66 | 571.96K |
| Aug 28, 2026 | $13.48 | $13.65 | $12.97 | $13.23 | 350.57K |
| Aug 27, 2026 | $14.13 | $14.175 | $13.41 | $13.48 | 252.5K |
| Aug 26, 2026 | $14.17 | $14.28 | $13.59 | $14.11 | 343.01K |
| Aug 25, 2026 | $13.79 | $14.4418 | $13.60 | $13.79 | 340.39K |
| Aug 24, 2026 | $13.91 | $13.91 | $13.03 | $13.67 | 228.58K |
| Aug 21, 2026 | $13.74 | $14.25 | $13.70 | $14.02 | 326.55K |
| Aug 20, 2026 | $14.76 | $14.76 | $13.20 | $13.57 | 764.81K |
| Aug 19, 2026 | $14.57 | $15.06 | $14.475 | $15.01 | 293.2K |
| Aug 18, 2026 | $14.09 | $14.53 | $14.07 | $14.22 | 322.43K |
The latest Smart Investors Daily articles mentioning EVMN.
EVMN research
Company profile and research snapshot.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | RBC Capital | Outperform | — |
| Sep 9, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 26, 2026 | Needham | Buy | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Evommune stock dropped Wednesday after its experimental eczema treatment flopped in midstage testing. The bearish news followed another miss for the drug in treating hives.
Benzinga · Sep 9, 2026
Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.
Yahoo · Sep 9, 2026
On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis. Phase 2b Clinical Trial Findings The study evaluated the efficacy and safety profile of oral EVO756, a Mas-related G-protein coupled receptor X2 antagonist. The trial enrolled 121 adult patients with moderate-to-severe atopic dermatitis over an active 12-week treatment period, with researchers mon
Benzinga · Sep 9, 2026
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EVMN.
